Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx is a global leader in bronchoscopic lung volume reduction technology, providing a minimally invasive solution for patients with severe emphysema. The recent leadership transition and emphasis on commercial focus and operating discipline indicate a commitment to improving execution and driving revenue growth. The company's strong financials and adequate runway suggest a positive outlook, but consistent execution and increased procedure growth will be key factors for investors to regain confidence in the company's potential.

Bears say

Pulmonx is facing challenges in the U.S. and China, with disruption in U.S. sales and the absence of China sales due to registration renewal. Despite this, management remains optimistic and expects a sequential improvement in revenue growth through 2026 and a return to growth in both U.S. and international markets in the back half of the year. However, the company's cash burn of $23M and the decline in U.S. sales in the latest quarter raise concerns about their financial stability.

Pulmonx (LUNG) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Pulmonx (LUNG) has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.